Replies to post #160740 on Biotech Values

[DewDiligence]

GILD–(ABBV/BMY)—If patients are producing as little as 8 weeks of revenue and you got to recoup $11B, you might be tempted to overprice and leave ABBV and BMY some room to compete on price.

In the US, the Sofosbuvir price will be >$100K per 8-week treatment course, IMO. However, GILD may impose a ceiling on the cumulative amount charged for a given patient, which finesses the disincentive for payers to favor shorter courses of treatment relative to (possibly more effective) longer courses.